Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

Core Insights - Ernexa Therapeutics is set to present data from its innovative cell therapy platform at the 67th ASH Annual Meeting, highlighting its potential in treating advanced cancer and autoimmune diseases [1][2]. Company Overview - Ernexa Therapeutics (NASDAQ: ERNA) focuses on developing novel cell therapies, particularly through engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs) [4]. - The company aims to provide scalable, off-the-shelf treatment solutions without the need for patient-specific cell harvesting [4]. Lead Products - ERNA-101 is Ernexa's lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells, with an initial focus on ovarian cancer [5]. - ERNA-201 is another cell therapy product aimed at targeting inflammation and treating autoimmune diseases [5]. Presentation Details - The oral presentation will feature preclinical findings supporting ERNA-101, showcasing a unique approach to converting immunosuppressive tumor microenvironments into pro-inflammatory environments that enhance immune response [3]. - The presentation is scheduled for December 6, 2025, from 3:00 PM to 3:15 PM EST at the OCCC - Chapin Theater [3].